106 results on '"Helen W. Boucher"'
Search Results
102. Clinical implications of stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals
- Author
-
Yehuda Carmeli, Didier Pittet, George M. Eliopoulos, Helen W. Boucher, Stéphan Juergen Harbarth, and Sotirios Tsiodras
- Subjects
Microbiology (medical) ,Male ,medicine.medical_specialty ,Cefotetan ,Stenotrophomonas maltophilia ,Intubation/adverse effects ,Microbial Sensitivity Tests ,Pharmacotherapy ,Internal medicine ,Drug Resistance, Multiple, Bacterial ,Trimethoprim, Sulfamethoxazole Drug Combination ,medicine ,Hospitals/standards ,Humans ,Trimethoprim-Sulfamethoxazole Combination/ pharmacology/therapeutic use ,Antibacterial agent ,Retrospective Studies ,ddc:616 ,Stenotrophomonas maltophilia/drug effects/pathogenicity ,General Immunology and Microbiology ,biology ,business.industry ,Sulfamethoxazole ,Anti-Bacterial Agents/ pharmacology/therapeutic use ,Trimethoprim Resistance ,General Medicine ,Middle Aged ,biology.organism_classification ,medicine.disease ,Trimethoprim ,Hospitals ,Surgery ,Anti-Bacterial Agents ,Survival Rate ,Pneumonia ,Infectious Diseases ,Ticarcillin ,Gram-Negative Bacterial Infections/ drug therapy/microbiology/mortality ,Female ,Morbidity ,business ,Gram-Negative Bacterial Infections ,Intubation ,medicine.drug - Abstract
We conducted a retrospective case study at 2 tertiary care centers to determine the clinical implications of trimethoprim-sulfamethoxazole resistant Stenotrophomonas maltophilia (TSRSM). Of 69 reviewed cases (mean age, 57 y; male gender, 70%), 40 (58%) were classified as infections associated with TSRSM (respiratory tract, 14; soft tissue, 11; bloodstream, 8; other sites, 7). Severe underlying comorbidities (86%) and previous antibiotic exposure (99%) were common. Cefotetan (susceptibility, 55%), chloramphenicol (49%) and ticarcillin-clavulanate (45%) showed the highest in vitro activity against TSRSM, but were seldom used for therapy (7%). Among the 40 infected cases, 8 developed sepsis disorders and 8 died. Only 1 death could be directly attributed to autopsy-proven TSRSM infection (pneumonia). McCabe score (p = 0.03) and organ dysfunction (p = 0.006) were associated with an increased risk of death in infected patients; exposure to appropriate therapy tended to be protective against death (p = 0.08). 22 infected patients were treated medically; an additional procedure was necessary to clear the infection in 18 cases (surgery, 13; catheter removal, 5). Isolation precautions were rarely exercised, even in the presence of panresistant isolates. In summary, TSRSM-related infections occurred in severely ill patients with extensive exposure to the health-care system, and often required invasive procedures for cure. Infections were directly associated with severe morbidity, and tended to have an indirect rather than a direct impact on mortality.
- Published
- 2000
103. Reply to Bruss
- Author
-
Sara E. Cosgrove, G. Ralph Corey, Vance G. Fowler, Helen W. Boucher, and Adolf W. Karchmer
- Subjects
Microbiology (medical) ,Infectious Diseases ,business.industry ,Medicine ,business ,Classics - Published
- 2009
104. Rifampin-containing regimens for community-associated skin infection: a hazard without known benefit
- Author
-
Loren G. Miller and Helen W. Boucher
- Subjects
medicine.medical_specialty ,business.industry ,medicine.drug_class ,Antibiotics ,MEDLINE ,General Medicine ,Skin infection ,medicine.disease ,medicine.disease_cause ,Hazard ,Trimethoprim ,Methicillin-resistant Staphylococcus aureus ,Community associated ,Pharmacotherapy ,Internal medicine ,Emergency Medicine ,medicine ,business ,medicine.drug - Published
- 2009
105. Reply to Kunin: Rationale for Antibiotic Development Incentives
- Author
-
Helen W. Boucher, John S. Bradley, W. M. Scheld, David N. Gilbert, John E. Edwards, Brad Spellberg, and John G. Bartlett
- Subjects
Microbiology (medical) ,Infectious Diseases ,Incentive ,Public economics ,medicine.drug_class ,business.industry ,Antibiotics ,medicine ,business - Published
- 2008
106. Effect of an Investigational Vaccine for Preventing Staphylococcus aureus Infections After Cardiothoracic Surgery
- Author
-
Robert F. Betts, Edson D. Moreira, Yehuda Carmeli, Vance G. Fowler, Keith B. Allen, Ajoke Sobanjo-ter Meulen, Jonathan Hartzel, Matthew T. Onorato, Dalya Guris, Nicholas A. Kartsonis, Tessie McNeely, Moustafa Moustafa, G. Ralph Corey, Mark J. DiNubile, Frank Isgro, Steven S. Smugar, Helen W. Boucher, and Ivan S. F. Chan
- Subjects
Adult ,Male ,Staphylococcus aureus ,medicine.medical_specialty ,Adolescent ,Bacteremia ,Placebo ,Staphylococcal infections ,law.invention ,Young Adult ,Double-Blind Method ,Randomized controlled trial ,law ,Internal medicine ,Preoperative Care ,medicine ,Humans ,Surgical Wound Infection ,Adverse effect ,Aged ,Aged, 80 and over ,business.industry ,Cardiovascular Surgical Procedures ,Mortality rate ,Vaccination ,Staphylococcal Vaccines ,General Medicine ,Middle Aged ,Staphylococcal Infections ,Thoracic Surgical Procedures ,Interim analysis ,medicine.disease ,Sternotomy ,Surgery ,Cardiothoracic surgery ,Female ,business - Abstract
Importance Infections due to Staphylococcus aureus are serious complications of cardiothoracic surgery. A novel vaccine candidate (V710) containing the highly conserved S aureus iron surface determinant B is immunogenic and generally well tolerated in volunteers. Objective To evaluate the efficacy and safety of preoperative vaccination in preventing serious postoperative S aureus infection in patients undergoing cardiothoracic surgery. Design, Setting, and Participants Double-blind, randomized, event-driven trial conducted between December 2007 and August 2011 among 8031 patients aged 18 years or older who were scheduled for full median sternotomy within 14 to 60 days of vaccination at 165 sites in 26 countries. Intervention Participants were randomly assigned to receive a single 0.5-mL intramuscular injection of either V710 vaccine, 60 μg (n = 4015), or placebo (n = 4016). Main Outcome Measures The primary efficacy end point was prevention of S aureus bacteremia and/or deep sternal wound infection (including mediastinitis) through postoperative day 90. Secondary end points included all S aureus surgical site and invasive infections through postoperative day 90. Three interim analyses with futility assessments were planned. Results The independent data monitoring committee recommended termination of the study after the second interim analysis because of safety concerns and low efficacy. At the end of the study, the V710 vaccine was not significantly more efficacious than placebo in preventing either the primary end points (22/3528 V710 vaccine recipients [2.6 per 100 person-years] vs 27/3517 placebo recipients [3.2 per 100 person-years]; relative risk, 0.81; 95% CI, 0.44-1.48; P = .58) or secondary end points despite eliciting robust antibody responses. Compared with placebo, the V710 vaccine was associated with more adverse experiences during the first 14 days after vaccination (1219/3958 vaccine recipients [30.8%; 95% CI, 29.4%-32.3%] and 866/3967 placebo recipients [21.8%; 95% CI, 20.6%-23.1%], including 797 [20.1%; 95% CI, 18.9%-21.4%] and 378 [9.5%; 95% CI, 8.6%-10.5%] with injection site reactions and 66 [1.7%; 95% CI, 1.3%-2.1%] and 51 [1.3%; 95% CI, 1.0%-1.7%] with serious adverse events, respectively) and a significantly higher rate of multiorgan failure during the entire study (31 vs 17 events; 0.9 [95% CI, 0.6-1.2] vs 0.5 [95% CI, 0.3-0.8] events per 100 person-years; P = .04). Although the overall incidence of vaccine-related serious adverse events (1 in each group) and the all-cause mortality rate (201/3958 vs 177/3967; 5.7 [95% CI, 4.9-6.5] vs 5.0 [95% CI, 4.3-5.7] deaths per 100 person-years; P = .20) were not statistically different between groups, the mortality rate in patients with staphylococcal infections was significantly higher among V710 vaccine than placebo recipients (15/73 vs 4/96; 23.0 [95% CI, 12.9-37.9] vs 4.2 [95% CI, 1.2-10.8] per 100 person-years; difference, 18.8 [95% CI, 8.0-34.1] per 100 person-years). Conclusions and Relevance Among patients undergoing cardiothoracic surgery with median sternotomy, the use of a vaccine against S aureus compared with placebo did not reduce the rate of serious postoperative S aureus infections and was associated with increased mortality among patients who developed S aureus infections. These findings do not support the use of the V710 vaccine for patients undergoing surgical interventions. Trial Registration clinicaltrials.gov Identifier: NCT00518687
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.